Login
Subscribe
Take a FREE Trial
About Us
Contact us
RSS
22 May 2013
Search
The Pharma Letter
Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe
Companies
Top Ten Companies //
Browse A - Z of companies
Merck KGaA
(Merck)
Merck
(Merck KGaA)
Pfizer
Roche
Novartis
GlaxoSmithKline
(GSK)
GSK
(GlaxoSmithKline)
Bristol-Myers Squibb
Lilly
Bayer
Browse the A - Z of Companies
#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
O
Obagi Medical Products
Oceana Therapeutics
Octapharma
OctoPlus
Oculus Innovative Sciences
Ohara Pharmaceutical
Olainfarm
Olden Group
OLIC
Omega Pharma
Omnivest
Onco Therapies
Oncodesign
OncoGenex
Oncolys BioPharma
OncoMed Pharmaceuticals
Onconova Therapeutics
Oncopeptides
OncoProd
Oncothyreon
Only for Children Pharmaceuticals
Ono Pharmaceutical
Onyx Pharmaceuticals
Onyx Scientific
Opexa Therapeutics
Ophthotech
OPKO Health
Optimer Biotechnology
Optimer Pharmaceuticals
Opus Group
OraPharma
Orchid Chemicals & Pharmaceuticals
Orchid Healthcare
Orexa
Orexigen Therapeutics
Orexo AB
Organon
OriGene Technologies
Orion Corp
Orion Laboratories
Orion Pharma
Orphan Therapeutics
Orphazyme
Ortho Centocor
Ortho-McNeil
Ortho-McNeil-Janssen
OSI Pharmaceuticals
Osiris Therapeutics
Ossianix
Osteologix
Osteotech
Osteros Biomedica
Othera Pharmaceuticals
Otsuka
OvaMed
Owen Mumford
Oxford BioMedica
Oxford BioTherapeutics
Oxford Cancer Biomarkers
OXiGENE
Hot Topics
Most Read
Is failure to adopt business process management putting the pharma industry at risk?
Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
New Zealand declines Alexion's funding application for Solaris
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
Is failure to adopt business process management putting the pharma industry at risk?
Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
New Zealand declines Alexion's funding application for Solaris
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations